HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b

Adriano M Pellicelli, Mario Romano, Tommaso Stroffolini, Ettore Mazzoni, Fabrizio Mecenate, Roberto Monarca, Antonio Picardi, Maria Elena Bonaventura, Cristina Mastropietro, Pascal Vignally, Arnaldo Andreoli, Massimo Marignani, Cecilia D'Ambrosio, Lucia Miglioresi, Lorenzo Nosotti, Olga Mitidieri, Umberto Vespasiani Gentilucci, Claudio Puoti, Giuseppe Barbaro, Angelo Barlattani, Caterina Furlan, Giorgio Barbarini, CLEO Group, Adriano M Pellicelli, Mario Romano, Tommaso Stroffolini, Ettore Mazzoni, Fabrizio Mecenate, Roberto Monarca, Antonio Picardi, Maria Elena Bonaventura, Cristina Mastropietro, Pascal Vignally, Arnaldo Andreoli, Massimo Marignani, Cecilia D'Ambrosio, Lucia Miglioresi, Lorenzo Nosotti, Olga Mitidieri, Umberto Vespasiani Gentilucci, Claudio Puoti, Giuseppe Barbaro, Angelo Barlattani, Caterina Furlan, Giorgio Barbarini, CLEO Group

Abstract

Background: The impact of viral subtype on the rate of sustained virological response (SVR) to antiviral therapy in patients chronically infected with hepatitis C genotype 1 subtype 1a and 1b has not been extensively investigated. The aim of this study is to determine whether the HCV genotype 1 subtypes 1a and 1b respond differently to treatment with PEGylated interferon (PEG-IFN) plus ribavirin.

Methods: For 48 weeks, 388 "naïve"genotype 1 patients were treated weekly with PEG-IFN α-2a or PEG-INF α-2b combined with daily ribavirin (1000-1200 mg/day). The numbers of patients in whom HCV-RNA was undetectable were compared after 4 (rapid virological response, RVR), 12 (early virological response, EVR), and 48 (end treatment virological response, ETR) weeks of treatment as well as 24 weeks after the last treatment (sustained virological response, SVR).

Results: The rate of SVR was higher in subtype 1a patients than subtype 1b patients (55% vs. 43%; p < 0.02). Multiple logistic regression analysis showed that infection with genotype 1a (odds ratio(OR) : 1.8; 95% confidence interval (CI): 1.4 to 4.1), age < 50 years (OR:7.0; 95% CI 1.1 to 21.2), alanine aminotransferase level (ALT)<100 IU/ml (OR:2.1; 95% CI: 1.3 to3.5), HCV-RNA < 5.6 log10 IU/ml (OR: 3.2; 95% CI: 2.7 to 6.9) and fibrosis score < S3 (OR: 3.8; 95% CI:3.2 to 7.4), were all independent predictors of SVR.

Conclusion: Dual antiviral therapy is more effective against HCV subtype 1a than against subtype 1b and this difference is independent of other factors that may favour viral clearance.

Trial registration: ClinicalTrials.gov Identifier: NCT01342003.

Figures

Figure 1
Figure 1
Rapid virological response (RVR), early virological response (EVR), end treatment virological response (ETR), sustained virological response (SVR) and drop out in genotype 1 subtypes 1a and 1b patients.

References

    1. McHutchison JG, Everson GT, Gordon SC. et al.PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360:1827–1838. doi: 10.1056/NEJMoa0806104.
    1. Kwo PY, Lawitz EJ, McCone J. et al.SPRINT-1 investigators. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010;376:705–716. doi: 10.1016/S0140-6736(10)60934-8.
    1. Fried MW, Shiffman ML, Reddy K. et al.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982. doi: 10.1056/NEJMoa020047.
    1. Hadziyannis SJ, Sette H Jr, Morgan TR. et al.PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–355.
    1. Cheng WS, Roberts SK, McCaughan G. Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. J Hepatol. 2010;53:616–623. doi: 10.1016/j.jhep.2010.04.024.
    1. Bruno S, Cammà C, Di Marco V. et al.Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial. Hepatol. 2004;41:474–481. doi: 10.1016/j.jhep.2004.05.012.
    1. Rizzetto M, Colombo M, Ascione A. et al.Effectiveness of hepatitis C virus treatment in real life practice: a prospective observational multicenter study in Italy (PROBE) J Hepatol. 2008;2(48):S311.
    1. Legrand-Abravanel F, Colson P, Leguillou-Guillemette L. et al.Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. J MedVirol. 2009;81:2029–2035.
    1. Nicot F, Alric L, Barange K. et al.Influence of genotype 1 subtypes on the virus response to Peg interferon alpha-2a plus ribavirin therapy. J Med Virol. 2011;83:437–444. doi: 10.1002/jmv.21976.
    1. Rosina F, Tosti ME, Borghesio E. et al.PEG-IFN for chronic hepatitis C in clinical practice: the prospective phase of the AIFA study. Dig Liv Dis. 2012;44S:s12.
    1. Knodell RG, Ishak KG, Black WC. et al.Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1:431–435. doi: 10.1002/hep.1840010511.
    1. Dienstag JL, McHutchinson J. American Gastroenterological association technical review on the management of hepatitis C. Gastroenterology. 2006;130:231–264. doi: 10.1053/j.gastro.2005.11.010.
    1. Zein NN, Rakela EL, Krawitt KR, Reddy KR, Tominaga T, Persing DH. Hepatitis C virus genotypes in United States: epidemiology, pathogenicity, and response to interferon therapy. Ann Intern Med. 1996;125:634–639.
    1. Zein NN. Clinical significance of hepatitis C virus genotypes. ClinMicrobiol Rev. 2000;13:223–235.
    1. Nevens E, Van Vlierberghe H, D’Heygere E. et al.BERNAR-1 Study Group. A randomized open label, multicenter studyevaluating the efficacy of peginterferon alfa 2a, in combination with ribavirin, in naïve and relapsed chronic hepatitis C patient. Acta Gastroenterol Belg. 2010;73:223–228.
    1. Yu JW, Wang GQ, Sun LJ, Li XG, Li SC. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J GastroenterolHepatol. 2007;22:832–836.
    1. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology. 2010;138:447–462. doi: 10.1053/j.gastro.2009.11.055.
    1. McHutchison JG, Lawitz EJ, Shiffman ML. et al.Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580–593. doi: 10.1056/NEJMoa0808010.
    1. Ascione A, De Luca M, Tartaglione MT. et al.Peginterferon alfa-2a plus ribavirin is nore effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology. 2010;138:116–122. doi: 10.1053/j.gastro.2009.10.005.
    1. Rumi MG, Aghemo A, Prati GM. et al.Randomized study of peginterferon alfa2a plus ribavirin vs peginterferon alfa2b plus ribavirin in chronic hepatitis C. Gastroenterology. 2010;138:108–115. doi: 10.1053/j.gastro.2009.08.071.
    1. Rumi MG, Aghemo A, Prati GM. Comparative trials of peginterferon alfa-2a and peginterferon alfa-2b for chronic hepatitis C. J Viral Hepatol. 2012;19:37–41.
    1. Thompson AJ, Muir AJ, Sulkowski MS. et al.Interleukin-28B polymorphism improves viral kinetics and is the strongestpretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;2010(139):120–129.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться